J 
Jiangsu Sinopep Allsino Biopharmaceutical Co 688076.SS · CNY
Health Care · Shanghai · 🇨🇳 China
27.90
+1.31%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥1.94bn
FY2016FY2025
Net income
CN¥327.0m
FY2016FY2025
Free cash flow
−CN¥685.8m
FY2016FY2025
Shareholders' equity
CN¥2.99bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥1.94bn | CN¥1.62bn | CN¥1.03bn | CN¥651.3m | CN¥643.9m | CN¥566.9m | CN¥371.5m | CN¥255.5m | CN¥228.9m | CN¥8.5m |
| Research and development | CN¥251.9m | CN¥227.4m | CN¥124.9m | CN¥69.5m | CN¥63.1m | CN¥60.5m | CN¥47.7m | CN¥35.1m | CN¥17.7m | CN¥15.5m |
| Operating income | CN¥400.0m | CN¥448.2m | CN¥189.7m | CN¥124.9m | CN¥128.3m | CN¥155.7m | CN¥56.8m | CN¥31.4m | CN¥56.6m | −CN¥75.7m |
| Net income | CN¥327.0m | CN¥404.4m | CN¥162.9m | CN¥129.1m | CN¥115.4m | CN¥123.4m | CN¥48.6m | CN¥43.9m | CN¥41.9m | −CN¥74.8m |
| Diluted earnings per share | 1.03 | 1.35 | 0.53 | 0.44 | 0.38 | 0.56 | 0.21 | 0.20 | 0.32 | -1.25 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥6.74bn | CN¥5.08bn | CN¥3.55bn | CN¥2.52bn | CN¥2.13bn | CN¥1.40bn | CN¥1.24bn | CN¥1.05bn | CN¥611.5m | CN¥160.1m |
| Cash and short-term investments | — | CN¥779.4m | CN¥749.1m | CN¥443.0m | CN¥679.0m | CN¥149.7m | CN¥58.1m | CN¥192.2m | CN¥24.4m | CN¥1.8m |
| Total liabilities | CN¥3.74bn | CN¥2.40bn | CN¥1.36bn | CN¥597.4m | CN¥318.1m | CN¥429.5m | CN¥405.5m | CN¥265.5m | CN¥290.3m | CN¥125.2m |
| Debt | CN¥1.32bn | CN¥1.51bn | CN¥849.7m | CN¥320.2m | CN¥83.6m | CN¥251.7m | CN¥200.6m | CN¥88.9m | CN¥132.5m | CN¥105.9m |
| Shareholders' equity | CN¥2.99bn | CN¥2.66bn | CN¥2.17bn | CN¥1.91bn | CN¥1.81bn | CN¥963.3m | CN¥834.3m | CN¥778.4m | CN¥321.2m | CN¥35.0m |
| Shares outstanding | 319m | 300m | 305m | 292m | 307m | 220m | 235m | 215m | 131m | 60m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥681.2m | CN¥400.1m | CN¥350.2m | CN¥29.3m | CN¥180.7m | CN¥141.4m | CN¥46.1m | CN¥96.1m | CN¥11.1m | −CN¥22.0m |
| Capital spending | −CN¥1.37bn | −CN¥1.09bn | −CN¥660.6m | −CN¥438.4m | −CN¥233.4m | −CN¥111.3m | −CN¥276.4m | −CN¥197.5m | −CN¥73.3m | −CN¥11.1m |
| Free cash flow | −CN¥685.8m | −CN¥690.0m | −CN¥310.4m | −CN¥409.1m | −CN¥52.6m | CN¥30.1m | −CN¥230.3m | −CN¥101.4m | −CN¥62.2m | −CN¥33.1m |
| Dividends paid | −CN¥239.6m | −CN¥118.8m | −CN¥57.6m | −CN¥32.0m | −CN¥6.0m | −CN¥11.6m | −CN¥4.5m | −CN¥8.4m | −CN¥59.1m | — |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥586.7m | CN¥553.0m | CN¥415.6m | CN¥478.9m | CN¥482.7m | CN¥565.6m | CN¥372.5m | CN¥420.8m |
| Operating income | CN¥216.0m | CN¥208.0m | −CN¥91.9m | CN¥152.5m | CN¥176.5m | CN¥177.5m | CN¥58.8m | CN¥130.5m |
| Net income | CN¥85.6m | CN¥129.5m | −CN¥117.5m | CN¥134.5m | CN¥157.4m | CN¥152.6m | CN¥54.1m | CN¥123.1m |
| Diluted earnings per share | 0.27 | 0.41 | -0.37 | 0.42 | 0.49 | 0.48 | 0.18 | 0.41 |
| Cash from operations | — | — | — | CN¥68.0m | CN¥170.0m | CN¥146.0m | — | CN¥69.0m |
| Capital spending | −CN¥213.0m | −CN¥167.0m | −CN¥343.0m | −CN¥337.0m | −CN¥333.0m | −CN¥353.0m | −CN¥439.0m | −CN¥322.0m |
| Free cash flow | — | — | — | −CN¥269.0m | −CN¥163.0m | −CN¥207.0m | — | −CN¥253.0m |
| Total assets | CN¥7.07bn | CN¥6.82bn | CN¥6.74bn | CN¥6.69bn | CN¥5.90bn | CN¥5.44bn | CN¥5.08bn | CN¥4.44bn |
| Cash and short-term investments | — | — | — | CN¥1.08bn | CN¥770.2m | CN¥734.7m | CN¥779.4m | CN¥661.5m |
| Debt | CN¥1.27bn | CN¥1.32bn | CN¥1.32bn | CN¥1.61bn | CN¥1.87bn | CN¥1.60bn | CN¥1.49bn | CN¥1.23bn |
| Shareholders' equity | CN¥3.09bn | CN¥3.12bn | CN¥2.99bn | CN¥3.11bn | CN¥2.96bn | CN¥2.82bn | CN¥2.66bn | CN¥2.62bn |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 44.0% | 27.9% | 71.6% |
| Operating income | 47.4% | 20.8% | — |
| Net income | 36.3% | 21.5% | — |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Operating margin | 23.8% | 22.1% | 22.4% | 20.2% |
| Net margin | 20.5% | 19.5% | 19.5% | 17.6% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Price to earnings | 36.7 | 27.5 | 60.0 | 37.0 | 78.6 |
| Price to sales | 6.2 | 6.8 | 9.5 | 7.3 | 14.1 |
Dividends and splits
Per share, in the currency the company pays
Paid for 4 years. Last went ex-dividend on 12 Jun 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Paid in the year | 0.35 | 0.571 | 0.357 | 0.143 | 0.107 |
- 7-for-5 split · 12 Jun 2025
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.